Costs and Payer Questions A patient-specific and complicated manufacturing process such as CAR T is expected to be costly. The cost of the first CAR T cell therapy from Novartis …
CAR T-Cell Therapy HCP Guide – The Costs Involved in CAR T-Cell Therapy Read More
March 2, 2018 (Medical News Today) At present, the most common types of treatment for cancer – the leading cause of death – are chemotherapy, radiation, surgery, and hormonal therapy, …
The state of cancer: Are we close to a cure? Read More
November 28, 2017 (Discovery Medicine) Glioblastoma remains a major unmet medical need in the field of oncology. With less than 10% of patients surviving five years from initial diagnosis, it …
Immunotherapy for Glioblastoma: On the Sidelines or in the Game? Read More
March 23, 2018 (Medical News Today) A biodegradable gel has been developed to stop the recurrence of cancer. Scientists at the Dana-Farber Cancer Institute in Boston, MA, created a gel …
Cancer: How a novel gel could halt its return Read More
February 19, 2018 (YouTube) Constantine Tam, MD, FRACP, FRCPA, of Peter MacCallum Cancer Centre, Melbourne, Australia. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in …
VIDEO: CAR T-cells for CLL Read More
February 15, 2018 (YouTube) Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses the impact of CAR T-cell therapy for patients with acute lymphoblastic leukemia (ALL).
VIDEO: The Impact of CAR T-Cell Therapy on ALL Read More
October 19, 2017 (HealthDay News) Yescarta (axicabtagene ciloleucel) has been approved by the U.S. Food and Drug Administration for individuals with certain types of large B-cell lymphoma who have not …
Gene Tx Approved for Certain Types of B-Cell Lymphoma Read More
December 13, 2017 (Medical News Today) Lung cancer is the most common cause of cancer-related deaths worldwide. It is the second most common cancer among men and women in the …
Cancer: Some immune cells found to give tumors a helping hand Read More
October 12, 2017 (HealthDay News) Patients with severe neurotoxicity after infusion of CD19-targeted chimeric antigen receptor-modified T (CAR-T) cells have evidence of endothelial activation, according to a study published online …
Neurotoxicity Characterized After Infusion of CD19 CAR-T Cells Read More
Published on February 13, 2018 Sattva S. Neelapu, MD, discusses the safety and practical implications for axi-cel (KTE-C19) as part of the ZUMA-1 trial, as well as the future for …
Axi-Cel and Future of CAR T-Cell Therapy in Lymphoma Read More